<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40"><head><meta http-equiv=Content-Type content="text/html; charset=utf-8"><meta name=Generator content="Microsoft Word 12 (filtered medium)"><!--[if !mso]><style>v\:* {behavior:url(#default#VML);}
o\:* {behavior:url(#default#VML);}
w\:* {behavior:url(#default#VML);}
.shape {behavior:url(#default#VML);}
</style><![endif]--><style><!--
/* Font Definitions */
@font-face
{font-family:Wingdings;
panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
{font-family:Verdana;
panose-1:2 11 6 4 3 5 4 4 2 4;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0cm;
margin-bottom:.0001pt;
font-size:12.0pt;
font-family:"Times New Roman","serif";}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:blue;
text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
{mso-style-priority:99;
color:purple;
text-decoration:underline;}
p
{mso-style-priority:99;
margin:0cm;
margin-bottom:.0001pt;
font-size:12.0pt;
font-family:"Times New Roman","serif";}
p.preheader-container, li.preheader-container, div.preheader-container
{mso-style-name:preheader-container;
margin:0cm;
margin-bottom:.0001pt;
mso-line-height-alt:.75pt;
font-size:1.0pt;
font-family:"Times New Roman","serif";
display:none;}
span.greeting-tag
{mso-style-name:greeting-tag;}
span.footer-column
{mso-style-name:footer-column;}
span.footer-mobile-hidden
{mso-style-name:footer-mobile-hidden;}
span.EmailStyle22
{mso-style-type:personal-reply;
font-family:"Calibri","sans-serif";
color:#1F497D;}
.MsoChpDefault
{mso-style-type:export-only;
font-size:10.0pt;}
@page WordSection1
{size:612.0pt 792.0pt;
margin:72.0pt 72.0pt 72.0pt 72.0pt;}
div.WordSection1
{page:WordSection1;}
/* List Definitions */
@list l0
{mso-list-id:97717831;
mso-list-template-ids:-1197977254;}
@list l0:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:36.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1
{mso-list-id:132214240;
mso-list-template-ids:-87289160;}
@list l1:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:36.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2
{mso-list-id:255599611;
mso-list-template-ids:725745898;}
@list l2:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:36.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l3
{mso-list-id:372119957;
mso-list-template-ids:693663674;}
@list l3:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:36.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l4
{mso-list-id:405298954;
mso-list-template-ids:-1937200194;}
@list l4:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:36.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l5
{mso-list-id:972490762;
mso-list-template-ids:345532922;}
@list l5:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:36.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l6
{mso-list-id:1089695735;
mso-list-template-ids:1004569634;}
@list l6:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:36.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l7
{mso-list-id:1153793096;
mso-list-template-ids:1333964376;}
@list l7:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:36.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l8
{mso-list-id:1629437607;
mso-list-template-ids:-1117501432;}
@list l8:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:36.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l9
{mso-list-id:1890605876;
mso-list-template-ids:878446632;}
@list l9:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:36.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l10
{mso-list-id:2014797386;
mso-list-template-ids:78030880;}
@list l10:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:36.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l11
{mso-list-id:2029217108;
mso-list-template-ids:216170446;}
@list l11:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:36.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l12
{mso-list-id:2048215734;
mso-list-template-ids:-1144491312;}
@list l12:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:36.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l13
{mso-list-id:2135976778;
mso-list-template-ids:-1910218906;}
@list l13:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:36.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
ol
{margin-bottom:0cm;}
ul
{margin-bottom:0cm;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]--></head><body bgcolor=whitesmoke lang=EN-CA link=blue vlink=purple><div class=WordSection1><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'>Hi all:<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'>See below for the e-newsletter from UsToo.<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'>Thx.<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'>Glen<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'><o:p> </o:p></span></p><p class=MsoNormal><o:p> </o:p></p><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse'><tr><td style='padding:0cm 0cm 0cm 0cm'><div><p class=MsoNormal align=center style='text-align:center;mso-line-height-alt:.75pt'><span style='font-size:1.0pt'><img id="_x0000_i1025" src="http://r20.rs6.net/on.jsp?ca=fc958698-7619-4387-83c8-dbb90b6d80f7&a=1127669815285&c=1bc05c4a-6b5e-11e9-96cd-d4ae527b6fcc&ch=1bc4ebc0-6b5e-11e9-96cd-d4ae527b6fcc"><o:p></o:p></span></p></div></td></tr><tr><td style='padding:0cm 0cm 0cm 0cm'><div><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;background:whitesmoke;border-collapse:collapse;min-width: 100%'><tr><td style='padding:0cm 0cm 0cm 0cm'><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=612 style='width:459.0pt;border-collapse:collapse'><tr><td valign=top style='padding:11.25pt 3.75pt 11.25pt 3.75pt'><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse'><tr><td valign=top style='background:black;padding:.75pt .75pt .75pt .75pt'><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;background:black;border-collapse:collapse'><tr><td valign=top style='background:white;padding:0cm 0cm 0cm 0cm'><div><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse'><tr><td width="100%" valign=top style='width:100.0%;padding:0cm 0cm 0cm 0cm'><div><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse'><tr><td valign=top style='padding:7.5pt 0cm 7.5pt 0cm'><div><p class=MsoNormal align=center style='text-align:center'><img width=177 id="_x0000_i1026" src="https://files.constantcontact.com/5f7db5e8601/cbaea20a-28e5-47c3-b92c-99ff3917a167.jpg"><o:p></o:p></p></div></td></tr></table></div></td></tr></table></div><p class=MsoNormal align=center style='text-align:center'><o:p> </o:p></p><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse;min-width: 100%'><tr><td width="100%" valign=top style='width:100.0%;padding:0cm 0cm 0cm 0cm;word-wrap: break-word'><div><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse;word-wrap: break-word'><tr><td valign=top style='padding:7.5pt 15.0pt 7.5pt 15.0pt'><div><div><p class=MsoNormal align=center style='text-align:center'><span style='font-family:"Arial","sans-serif";color:#333333'><a href="http://r20.rs6.net/tn.jsp?f=001FNOFw02__L_UrU61Akw_J25j2tyZwWw7EaQe18GFz6UUJRnrfNHW4KkeSaJBl5nLQtrRgIcmQIRzc1JE6LB0PO7EvbePrloJ_WswNAM9FE0G8BoHqz-RWeVZZmYBox5hi4TXCaG150Y=&c=9Svlxdca_7izPUd2isOX2mUzolFU0Tlc8o7Ur_N35HRkSQnpPsxjWQ==&ch=Uqr8NkUnrTsrRRvTm-56RILbRua8HOO5fdQBASG-yys-olxp5ZgPrw==" target="_blank"><span style='color:#0078C1'>www.ustoo.org</span></a> </span><span style='font-family:"Arial","sans-serif";color:#141414'> |</span><span style='font-family:"Arial","sans-serif";color:#333333'> <a href="http://r20.rs6.net/tn.jsp?f=001FNOFw02__L_UrU61Akw_J25j2tyZwWw7EaQe18GFz6UUJRnrfNHW4HRDMha5YTX4LkDZaX1KPOJjP0iOLk8L0f8TzlD91fE31-DJHCDXg7SomoUSIR5P3FT3jqDAzcoMG08ClLtscursqLIg5YMB_m62kSaVDY3Sr808-yuXbNcZJFR7y9GhUuxYMbB3jYBk&c=9Svlxdca_7izPUd2isOX2mUzolFU0Tlc8o7Ur_N35HRkSQnpPsxjWQ==&ch=Uqr8NkUnrTsrRRvTm-56RILbRua8HOO5fdQBASG-yys-olxp5ZgPrw==" target="_blank"><span style='color:#0078C1'>Donate</span></a> </span><span style='font-family:"Arial","sans-serif";color:#141414'> |</span><span style='font-family:"Arial","sans-serif";color:#333333'> </span><u><span style='font-family:"Arial","sans-serif";color:#1E7CE8'><a href="http://r20.rs6.net/tn.jsp?f=001FNOFw02__L_UrU61Akw_J25j2tyZwWw7EaQe18GFz6UUJRnrfNHW4JFkOwVjAFiUPkoYIpHKeBbaP93Ha5YMfS6hWHkL32nStQO50zDwUBxt3H4Ufq055tn8ESXYDsWe14nivYbFNONtklqZcOCZbA==&c=9Svlxdca_7izPUd2isOX2mUzolFU0Tlc8o7Ur_N35HRkSQnpPsxjWQ==&ch=Uqr8NkUnrTsrRRvTm-56RILbRua8HOO5fdQBASG-yys-olxp5ZgPrw=="><span style='color:#1E7CE8'>View in Browser</span></a></span></u><span style='font-family:"Arial","sans-serif";color:#333333'> <o:p></o:p></span></p><p class=MsoNormal align=right style='text-align:right'><span style='font-family:"Arial","sans-serif";color:#333333'><o:p> </o:p></span></p><p class=MsoNormal align=center style='text-align:center'><i><span style='font-family:"Arial","sans-serif";color:#333333'>Made possible by a charitable contribution from </span></i><span style='font-family:"Arial","sans-serif";color:#333333'><a href="http://r20.rs6.net/tn.jsp?f=001FNOFw02__L_UrU61Akw_J25j2tyZwWw7EaQe18GFz6UUJRnrfNHW4HRDMha5YTX4qh-SNER7iEankpI_7sKEY5j5Fq1In4FySf6uuiwgZqSC-tg7bZBFrwyfZswvcwTmVmfyjSycbaM=&c=9Svlxdca_7izPUd2isOX2mUzolFU0Tlc8o7Ur_N35HRkSQnpPsxjWQ==&ch=Uqr8NkUnrTsrRRvTm-56RILbRua8HOO5fdQBASG-yys-olxp5ZgPrw==" target="_blank"><b><i><span style='color:#0078C1'>Bayer</span></i></b></a> <o:p></o:p></span></p><p class=MsoNormal align=center style='text-align:center'><i><span style='font-family:"Arial","sans-serif";color:#0078C1'>Navigation Tip: Click on blue text that’s italicized, underlined and in bold for link to more information.</span></i><span style='font-family:"Arial","sans-serif";color:#333333'><o:p></o:p></span></p><p class=MsoNormal align=center style='text-align:center'><span style='font-family:"Arial","sans-serif";color:#333333'><o:p> </o:p></span></p><div><p class=MsoNormal><span class=greeting-tag><span style='font-family:"Arial","sans-serif";color:black'>Hello Glen,</span></span><span style='font-family:"Arial","sans-serif";color:#333333'><o:p></o:p></span></p></div><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:#333333'><o:p> </o:p></span></p></div><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:black'>We hope you are doing well and helping to raise awareness for prostate cancer throughout the month of September.</span><span style='font-family:"Arial","sans-serif";color:#333333'><o:p></o:p></span></p></div><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:#333333'><o:p> </o:p></span></p></div><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:black'>We’re pleased to provide you with </span><b><span style='font-family:"Arial","sans-serif";color:#006DB0'>some of the latest Prostate Cancer News You Can Use</span></b><span style='font-family:"Arial","sans-serif";color:black'>. In addition to the following updates and information that may be of interest to you, the titles of prostate cancer news articles are listed below along with a link to the Us TOO web page that provides access to the full text for each article.</span><span style='font-family:"Arial","sans-serif";color:#333333'> <o:p></o:p></span></p></div><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:#333333'><o:p> </o:p></span></p></div><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:#333333'>If you need any conversation-starters about September being </span><b><span style='font-family:"Arial","sans-serif";color:#0070C0'>Prostate Cancer Awareness Month</span></b><span style='font-family:"Arial","sans-serif";color:#333333'>, here are some quick facts about the disease:<o:p></o:p></span></p></div><p class=MsoNormal style='margin-left:30.0pt;text-indent:-12.0pt;mso-list:l1 level1 lfo1'><![if !supportLists]><span style='font-size:10.0pt;font-family:Symbol;color:#333333'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'> </span></span></span><![endif]><span style='font-family:"Arial","sans-serif";color:#333333'>Nearly 175,000 men will be diagnosed with prostate cancer in 2019<o:p></o:p></span></p><p class=MsoNormal style='margin-left:30.0pt;text-indent:-12.0pt;mso-list:l1 level1 lfo1'><![if !supportLists]><span style='font-size:10.0pt;font-family:Symbol;color:#333333'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'> </span></span></span><![endif]><span style='font-family:"Arial","sans-serif";color:#333333'>More than 31,000 men in the U.S. will die this year from prostate cancer; it’s the second largest cancer killer of men following lung cancer<o:p></o:p></span></p><p class=MsoNormal style='margin-left:30.0pt;text-indent:-12.0pt;mso-list:l1 level1 lfo1'><![if !supportLists]><span style='font-size:10.0pt;font-family:Symbol;color:#333333'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'> </span></span></span><![endif]><span style='font-family:"Arial","sans-serif";color:#333333'>Prostate cancer has no symptoms until it’s advanced<o:p></o:p></span></p><p class=MsoNormal style='margin-left:30.0pt;text-indent:-12.0pt;mso-list:l1 level1 lfo1'><![if !supportLists]><span style='font-size:10.0pt;font-family:Symbol;color:#333333'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'> </span></span></span><![endif]><span style='font-family:"Arial","sans-serif";color:#333333'>The disease is always treatable; but if detected early, prostate cancer is often curable<o:p></o:p></span></p><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:#333333'><o:p> </o:p></span></p></div><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:#333333'>Find more information at: <a href="http://r20.rs6.net/tn.jsp?f=001FNOFw02__L_UrU61Akw_J25j2tyZwWw7EaQe18GFz6UUJRnrfNHW4EXYrzjvy5c_VW5mUSkQiN3xwQFusMrOWw7uwO33k4rbF8z8a6zD-0RvAoNQ-MpIyRFab_KLve1j8N3ijiALPhfd_OKWaoL_ugDE7IC_eY23&c=9Svlxdca_7izPUd2isOX2mUzolFU0Tlc8o7Ur_N35HRkSQnpPsxjWQ==&ch=Uqr8NkUnrTsrRRvTm-56RILbRua8HOO5fdQBASG-yys-olxp5ZgPrw==" target="_blank"><b><i><span style='color:#0070C0'>www.ustoo.org/Facts-And-Stats</span></i></b></a>. F</span><span style='font-family:"Arial","sans-serif";color:black'>ollow us on Facebook or Twitter and share our daily </span><b><span style='font-family:"Arial","sans-serif";color:#006DB0'>#ProstateCancerAwarenessMonth</span></b><span style='font-family:"Arial","sans-serif";color:black'> posts featuring stats and resources. </span><span style='font-family:"Arial","sans-serif";color:#333333'> <o:p></o:p></span></p></div><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:#333333'><o:p> </o:p></span></p></div><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:black'>We’d like to thank everyone who helped to make the </span><b><span style='font-family:"Arial","sans-serif";color:#006DB0'>15th Annual SEA Blue Chicago Prostate Cancer Walk and Run</span></b><b><span style='font-family:"Arial","sans-serif";color:black'> </span></b><span style='font-family:"Arial","sans-serif";color:black'>a huge success! More than 1,000 people gathered in Lincoln Park to raise awareness for prostate cancer along with funds to help Us TOO provide Support, Education, and Advocacy for the prostate cancer community at no charge. The </span><span style='font-family:"Arial","sans-serif";color:#333333'><a href="http://r20.rs6.net/tn.jsp?f=001FNOFw02__L_UrU61Akw_J25j2tyZwWw7EaQe18GFz6UUJRnrfNHW4IEO_J9vYKMFlk28cO-U1zdPlNDX7njhWU_LDI8x2LqM96uadv3wm4gVxdQi3oTyJ9oRrRvFUWbrvfmcT1gFwPEW_OP44SDy852sG6zsb6e4YE6hp9nH_5M=&c=9Svlxdca_7izPUd2isOX2mUzolFU0Tlc8o7Ur_N35HRkSQnpPsxjWQ==&ch=Uqr8NkUnrTsrRRvTm-56RILbRua8HOO5fdQBASG-yys-olxp5ZgPrw==" target="_blank"><b><i><span style='color:#006DB0'>SEA Blue website</span></i></b></a></span><span style='font-family:"Arial","sans-serif";color:black'> is open for donations until October 15.</span><span style='font-family:"Arial","sans-serif";color:#333333'> <o:p></o:p></span></p></div><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:#333333'><o:p> </o:p></span></p></div><div><p class=MsoNormal><b><span style='font-family:"Arial","sans-serif";color:#0070C0'>Free registration is now open for both of the Us TOO Pathways educational events.</span></b><span style='font-family:"Arial","sans-serif";color:#333333'> </span><span style='font-family:"Arial","sans-serif";color:black'>Prostate Cancer Pathways is a new, dynamic educational event and webcast series from Us TOO International for men with prostate cancer and their loved ones. The 2019 two-event Pathways series will include panel discussions featuring medical experts and patients addressing topics that are most important to men with prostate cancer, as determined by survey results from Us TOO support group leaders. Plan to attend in-person or watch the webcast with live audio and video from each of the two events:</span><span style='font-family:"Arial","sans-serif";color:#333333'> <o:p></o:p></span></p></div><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:#333333'><o:p> </o:p></span></p></div><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:#333333'>1. </span><span style='font-family:"Arial","sans-serif";color:black'>The</span><span style='font-family:"Arial","sans-serif";color:#333333'> </span><b><span style='font-family:"Arial","sans-serif";color:#006DB0'>Pathways</span></b><span style='font-family:"Arial","sans-serif";color:#333333'> </span><span style='font-family:"Arial","sans-serif";color:black'>event in Detroit is on Saturday, Oct. 12; </span><span style='font-family:"Arial","sans-serif";color:#333333'><a href="http://r20.rs6.net/tn.jsp?f=001FNOFw02__L_UrU61Akw_J25j2tyZwWw7EaQe18GFz6UUJRnrfNHW4HyiMmPlpcL4tVyA2M0h6wp75ujc7BXjeScDix4sE6995Z3aj27eroGHIVqT6fUgKS3dE9_-8tNGXjvoo6X0QHlKW9q0OxXuqN8z43UzU2Hh&c=9Svlxdca_7izPUd2isOX2mUzolFU0Tlc8o7Ur_N35HRkSQnpPsxjWQ==&ch=Uqr8NkUnrTsrRRvTm-56RILbRua8HOO5fdQBASG-yys-olxp5ZgPrw==" target="_blank"><b><i><span style='color:#0070C0'>CLICK HERE</span></i></b></a> to <o:p></o:p></span></p></div><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:#333333'>r</span><span style='font-family:"Arial","sans-serif";color:black'>egister for the webcast, or if you will be in Detroit to attend in person, </span><span style='font-family:"Arial","sans-serif";color:#333333'><o:p></o:p></span></p></div><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:#333333'><a href="http://r20.rs6.net/tn.jsp?f=001FNOFw02__L_UrU61Akw_J25j2tyZwWw7EaQe18GFz6UUJRnrfNHW4HyiMmPlpcL4vkxpXrN8motOgZN8cMToRxwsSaZv-ksu8oyo_GxG9L2dOrJxgBZ2V-_gCmM3YgJqjY-mhCRERJUJUAoVlSUoSpPV6mUfCRXtL7EL9cxbppk=&c=9Svlxdca_7izPUd2isOX2mUzolFU0Tlc8o7Ur_N35HRkSQnpPsxjWQ==&ch=Uqr8NkUnrTsrRRvTm-56RILbRua8HOO5fdQBASG-yys-olxp5ZgPrw==" target="_blank"><b><i><span style='color:#0070C0'>CLICK HERE</span></i></b></a> </span><span style='font-family:"Arial","sans-serif";color:black'>to register.</span><span style='font-family:"Arial","sans-serif";color:#333333'> <o:p></o:p></span></p></div><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:#333333'><o:p> </o:p></span></p></div><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:#333333'>2. The Pathways event </span><span style='font-family:"Arial","sans-serif";color:black'>in Chicago is on Saturday, Nov. 9; </span><span style='font-family:"Arial","sans-serif";color:#333333'><a href="http://r20.rs6.net/tn.jsp?f=001FNOFw02__L_UrU61Akw_J25j2tyZwWw7EaQe18GFz6UUJRnrfNHW4JFkOwVjAFiUcUpH20wbRBIMJhNjp4zYqKmG3CpBuLiOMuJnZrlJWJ9e9dhUvb8anCY8yRsD9csNYXFXFxsd4XTltZBMCBvqXy02ulJ1-v5m7KNAJD9NyEeRxdoaDoXLPDhKtBmWLklXzX0ql7KXFHg=&c=9Svlxdca_7izPUd2isOX2mUzolFU0Tlc8o7Ur_N35HRkSQnpPsxjWQ==&ch=Uqr8NkUnrTsrRRvTm-56RILbRua8HOO5fdQBASG-yys-olxp5ZgPrw==" target="_blank"><b><i><span style='color:#006DB0'>CLICK HERE</span></i></b></a> t</span><span style='font-family:"Arial","sans-serif";color:black'>o register for either online or in person attendance. For any questions on registration call Us TOO at 800-808-7866. </span><span style='font-family:"Arial","sans-serif";color:#333333'><o:p></o:p></span></p></div><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:#333333'><o:p> </o:p></span></p></div><div><p class=MsoNormal><b><span style='font-family:"Arial","sans-serif";color:#006DB0'>The </span></b><b><span style='font-family:"Arial","sans-serif";color:#0070C0'>Prostate Cancer Foundation has recently updated their Patient Guide</span></b><span style='font-family:"Arial","sans-serif";color:#333333'> to reflect the very latest research and discoveries for prostate cancer patients. <a href="http://r20.rs6.net/tn.jsp?f=001FNOFw02__L_UrU61Akw_J25j2tyZwWw7EaQe18GFz6UUJRnrfNHW4J9ZDZ3x_kgZxplGdauAuRPPbo4IXcUrqn80xmiJiy9cRI8ZwL65Qw6T3ngoQqFWuDoPPewzcPpGoQ3L5ZHgafqhCHgkvKYxsM70h-RE3s4xa1PE3_rX1OVq0t74LqYZJKw4cU795LBIcWrjNI9hjF4=&c=9Svlxdca_7izPUd2isOX2mUzolFU0Tlc8o7Ur_N35HRkSQnpPsxjWQ==&ch=Uqr8NkUnrTsrRRvTm-56RILbRua8HOO5fdQBASG-yys-olxp5ZgPrw==" target="_blank"><b><i><span style='color:#0070C0'>CLICK HERE</span></i></b></a> to download an updated digital copy. PCF is also offering </span><b><span style='font-family:"Arial","sans-serif";color:#0070C0'>"The Science of Living Well, Beyond Cancer."</span></b><span style='font-family:"Arial","sans-serif";color:#333333'> <a href="http://r20.rs6.net/tn.jsp?f=001FNOFw02__L_UrU61Akw_J25j2tyZwWw7EaQe18GFz6UUJRnrfNHW4JFkOwVjAFiUdrhfCjR0wggnzMNibU_D9rL3s58SoCXTetIphBKxAmBVYwwoh4cTwbbzAEWqp85WHqXCaf-6fWMxGNkTPVTrBtFX-fAs9hV2bcCKLB8D6os=&c=9Svlxdca_7izPUd2isOX2mUzolFU0Tlc8o7Ur_N35HRkSQnpPsxjWQ==&ch=Uqr8NkUnrTsrRRvTm-56RILbRua8HOO5fdQBASG-yys-olxp5ZgPrw==" target="_blank"><b><i><span style='color:#0070C0'>CLICK HERE</span></i></b></a> to download your free PDF.<o:p></o:p></span></p></div><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:#333333'><o:p> </o:p></span></p></div><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:#333333'>Check out the latest issue of the <a href="http://r20.rs6.net/tn.jsp?f=001FNOFw02__L_UrU61Akw_J25j2tyZwWw7EaQe18GFz6UUJRnrfNHW4EXYrzjvy5c_h9q54EGQonFCKT6l0k6EuWJNjW6Gc0OCxlhn8NqzrYS835yIPtVgboPS1tXzmtaUJ8qgIBcD7zFNnhB15Jq-hC383dRUG3PXWrpR4Bcvt0MsQYa4g9gOCoibEcuq5UCwZA1Hi-pAxBk=&c=9Svlxdca_7izPUd2isOX2mUzolFU0Tlc8o7Ur_N35HRkSQnpPsxjWQ==&ch=Uqr8NkUnrTsrRRvTm-56RILbRua8HOO5fdQBASG-yys-olxp5ZgPrw==" target="_blank"><b><i><span style='color:#0070C0'>EUROPA UOMO</span></i></b></a> newsletter for prostate cancer initiatives in Europe. And participate in the </span><b><span style='font-family:"Arial","sans-serif";color:#0070C0'>European Prostate Cancer</span></b><span style='font-family:"Arial","sans-serif";color:#333333'> <a href="http://r20.rs6.net/tn.jsp?f=001FNOFw02__L_UrU61Akw_J25j2tyZwWw7EaQe18GFz6UUJRnrfNHW4EXYrzjvy5c_qOeKUfzubMwSFOUrmhI-0ueIoUAxOw9BvdalObSuB5V963MMO4bWJqdIrVcJPDSN2WCxXnMtcR9n0LsdQySEa0GECxuSm7H-EeijB3VK2qw9OAmOf3BH9uYVmGzJ4peNgR021ayrXSs=&c=9Svlxdca_7izPUd2isOX2mUzolFU0Tlc8o7Ur_N35HRkSQnpPsxjWQ==&ch=Uqr8NkUnrTsrRRvTm-56RILbRua8HOO5fdQBASG-yys-olxp5ZgPrw==" target="_blank"><b><i><span style='color:#0070C0'>Quality of Life Survey</span></i></b></a> from Europa Uomo. The success of this online survey depends on a strong response rate by its member organizations in 27 countries.<o:p></o:p></span></p></div><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:#333333'><o:p> </o:p></span></p></div><div><p class=MsoNormal><b><span style='font-family:"Arial","sans-serif";color:#0070C0'>IRONMAN</span></b><span style='font-family:"Arial","sans-serif";color:#333333'> </span><b><span style='font-family:"Arial","sans-serif";color:#0070C0'>is a registry recruiting 5,000 men with advanced prostate cancer from nine countries.</span></b><span style='font-family:"Arial","sans-serif";color:#333333'> More than 366,000 men die of prostate cancer globally every year. Research on a man's type of prostate cancer, treatment and side effects will help inform what causes prostate cancer, how to stop or slow its progression, and how to provide the best possible care to enable men to live the best quality life possible. <a href="http://r20.rs6.net/tn.jsp?f=001FNOFw02__L_UrU61Akw_J25j2tyZwWw7EaQe18GFz6UUJRnrfNHW4E2WyzRT9YYDj5ztN3G7X4hsYzdiT0s2aHu4Qjkd988S6a85-7eJDcxWJK5ETyNLyUlpCQvXv5oTU21EjbqLkoxGxgMykJxHNg==&c=9Svlxdca_7izPUd2isOX2mUzolFU0Tlc8o7Ur_N35HRkSQnpPsxjWQ==&ch=Uqr8NkUnrTsrRRvTm-56RILbRua8HOO5fdQBASG-yys-olxp5ZgPrw==" target="_blank"><b><i><span style='color:#0070C0'>CLICK HERE</span></i></b></a> for details. <o:p></o:p></span></p></div><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:#333333'><o:p> </o:p></span></p></div><div><p class=MsoNormal><b><span style='font-family:"Arial","sans-serif";color:#0070C0'>The Metastatic Prostate Cancer Project is a nationwide genomic research study</span></b><span style='font-family:"Arial","sans-serif";color:#333333'> for men with metastatic and/or advanced prostate cancer. Patients can join online and participate by sharing their medical information and samples. The project’s goal is to release new data to help researchers better understand metastatic and advanced prostate cancer, and accelerate discoveries. <a href="http://r20.rs6.net/tn.jsp?f=001FNOFw02__L_UrU61Akw_J25j2tyZwWw7EaQe18GFz6UUJRnrfNHW4Pnzr0qRRpGcNRy8VEkLP0ZvSp2DEOCm47CEXF3Z8xirSwwCgLK0IkUaPBTe-xtr5s0rpwAztCXDp53DZVn5n9CbbewTiDo5cw==&c=9Svlxdca_7izPUd2isOX2mUzolFU0Tlc8o7Ur_N35HRkSQnpPsxjWQ==&ch=Uqr8NkUnrTsrRRvTm-56RILbRua8HOO5fdQBASG-yys-olxp5ZgPrw==" target="_blank"><b><i><span style='color:#0070C0'>CLICK HERE</span></i></b></a> to learn more.<o:p></o:p></span></p></div><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:#333333'><o:p> </o:p></span></p></div><div><p class=MsoNormal><b><span style='font-family:"Arial","sans-serif";color:#0070C0'>BRCA Blue</span></b><span style='font-family:"Arial","sans-serif";color:#333333'> is an initiative to help educate patients and caregivers about the </span><b><span style='font-family:"Arial","sans-serif";color:#0070C0'>connection between BRCA gene mutations and prostate cancer.</span></b><span style='font-family:"Arial","sans-serif";color:#333333'> While some people may have heard about BRCA genes and their relationship to breast and ovarian cancers, research has shown a connection to other cancers as well – including prostate cancer. Men who have a BRCA mutation are at a higher risk for developing prostate cancer than men without a BRCA mutation. To learn more about this important gene visit <a href="http://r20.rs6.net/tn.jsp?f=001FNOFw02__L_UrU61Akw_J25j2tyZwWw7EaQe18GFz6UUJRnrfNHW4GSLhNMYp2eJCjObjwxr3dC4qyd645DfYEm4grEzhBpK_35UuoeVaygqXZ4B4LOBpzSV59bXbMndm8CkcumwBOVb8gQFRy8zBA==&c=9Svlxdca_7izPUd2isOX2mUzolFU0Tlc8o7Ur_N35HRkSQnpPsxjWQ==&ch=Uqr8NkUnrTsrRRvTm-56RILbRua8HOO5fdQBASG-yys-olxp5ZgPrw==" target="_blank"><b><i><span style='color:#0070C0'>BRCABlue.com</span></i></b></a><b>.</b> <o:p></o:p></span></p></div><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:black'> </span><span style='font-family:"Arial","sans-serif";color:#333333'><o:p></o:p></span></p></div><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:#333333'>Recently, </span><b><span style='font-family:"Arial","sans-serif";color:#0070C0'>Congress expanded the geographic limits for exposure to Agent Orange</span></b><span style='font-family:"Arial","sans-serif";color:#333333'>. Veterans who served on vessels within 12 nautical miles seaward from the demarcation line of waters of Vietnam and Cambodia as defined in Public Law 116-23 (Blue Water Navy) between January 9, 1962, and May 7, 1975, are presumed to have been exposed to herbicides such as Agent Orange and may be entitled to service connection for conditions related to that exposure. Read more in the <a href="http://r20.rs6.net/tn.jsp?f=001FNOFw02__L_UrU61Akw_J25j2tyZwWw7EaQe18GFz6UUJRnrfNHW4J9ZDZ3x_kgZ3N__0hv5j1MmIEk0sxQuOIrAuy1nIY3LPIzCBIkGZEshsFHLc0hnBAan2-EmQvGwSfbhWUEa0ABCzC-6AkFzsmWPxfUqUo-w7nsGOsMujn0zPvvJUXI06w==&c=9Svlxdca_7izPUd2isOX2mUzolFU0Tlc8o7Ur_N35HRkSQnpPsxjWQ==&ch=Uqr8NkUnrTsrRRvTm-56RILbRua8HOO5fdQBASG-yys-olxp5ZgPrw==" target="_blank"><b><i><span style='color:#0070C0'>press release</span></i></b></a> and find additional information including a list of conditions in the <a href="http://r20.rs6.net/tn.jsp?f=001FNOFw02__L_UrU61Akw_J25j2tyZwWw7EaQe18GFz6UUJRnrfNHW4J9ZDZ3x_kgZavQ2XnLMcMTigt310gQ6oDF4MvOkpKCFGncVJmuyrpdZDGbffNAfYPgU63FaJ7rosxWE14jqz1TG57WzHopk5bCFjjatlJep9RBioXFnHa4=&c=9Svlxdca_7izPUd2isOX2mUzolFU0Tlc8o7Ur_N35HRkSQnpPsxjWQ==&ch=Uqr8NkUnrTsrRRvTm-56RILbRua8HOO5fdQBASG-yys-olxp5ZgPrw==" target="_blank"><b><i><span style='color:#0070C0'>fact sheet</span></i></b></a>.<o:p></o:p></span></p></div><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:#333333'><o:p> </o:p></span></p></div><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:black'>Weill Cornell Medicine, New York-Presbyterian Hospital, Columbia University Irving Medical Center and Memorial Sloan Kettering Cancer Center will co-host </span><b><span style='font-family:"Arial","sans-serif";color:#0070C0'>the 2nd Annual NYC Prostate Cancer Summit on Saturday, September 21, at the New York Academy of Medicine</span></b><span style='font-family:"Arial","sans-serif";color:black'> (1216 5th Avenue, New York, NY 10029). This FREE patient education event will last from 8AM – 2PM and cover topics such as the latest prostate cancer treatments and technologies, coping with side effects, clinical trials, genetics and more. </span><span style='font-family:"Arial","sans-serif";color:#333333'><a href="http://r20.rs6.net/tn.jsp?f=001FNOFw02__L_UrU61Akw_J25j2tyZwWw7EaQe18GFz6UUJRnrfNHW4JFkOwVjAFiUJvu5hOUa-U15ngMZ3RUFns2yAMwrE5V0_rNLqH2Y1DWhpkobjd6Xoi0GY3SVOuJRyJmksqsCQCS6KS8qiNTf5mi9YSh5t9XZ-UZQCR2tFSIdieiSUuGIctb8buiwEx5eFsKlO1g4Kok=&c=9Svlxdca_7izPUd2isOX2mUzolFU0Tlc8o7Ur_N35HRkSQnpPsxjWQ==&ch=Uqr8NkUnrTsrRRvTm-56RILbRua8HOO5fdQBASG-yys-olxp5ZgPrw==" target="_blank"><b><i><span style='color:#0070C0'>CLICK HERE</span></i></b></a></span><span style='font-family:"Arial","sans-serif";color:black'> to register. </span><span style='font-family:"Arial","sans-serif";color:#333333'><o:p></o:p></span></p></div><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:black'> </span><span style='font-family:"Arial","sans-serif";color:#333333'><o:p></o:p></span></p></div><div><p class=MsoNormal><b><span style='font-family:"Arial","sans-serif";color:#0070C0'>Malecare is hosting a Prostate Cancer Patient Conference on October 5</span></b><span style='font-family:"Arial","sans-serif";color:#333333'>. </span><span style='font-family:"Arial","sans-serif";color:black'>Presentations throughout the day will feature 12 physicians, including six from Memorial Sloan Kettering, breakfast, lunch, snacks and drinks. Discounted rooms are provided at the Intercontinental Barclay hotel in Manhattan. Register with the promotion code "UsTOO" for a 50% discount.</span><span style='font-family:"Arial","sans-serif";color:#333333'> <a href="http://r20.rs6.net/tn.jsp?f=001FNOFw02__L_UrU61Akw_J25j2tyZwWw7EaQe18GFz6UUJRnrfNHW4J9ZDZ3x_kgZOn_FEdqnA3aQ1mimab5QXglRe5zAM-rfqPQCDARGaU667qQ3leqAOcCJgd-TI2FidBCn9yLOvUgI3Bpb3FwsxtVzIFSGj-OuYTjawTE76bo=&c=9Svlxdca_7izPUd2isOX2mUzolFU0Tlc8o7Ur_N35HRkSQnpPsxjWQ==&ch=Uqr8NkUnrTsrRRvTm-56RILbRua8HOO5fdQBASG-yys-olxp5ZgPrw==" target="_blank"><b><i><span style='color:#0078C1'>CLICK HERE</span></i></b></a> </span><span style='font-family:"Arial","sans-serif";color:black'>for event information and registration.</span><span style='font-family:"Arial","sans-serif";color:#333333'> <o:p></o:p></span></p></div><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:#333333'><o:p> </o:p></span></p></div><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:black'>The National Alliance of State Prostate Cancer Coalitions – “</span><b><span style='font-family:"Arial","sans-serif";color:#006DB0'>The Prostate Cancer Alliance”- is pleased to present its 15th Annual Meeting GALA</span></b><span style='font-family:"Arial","sans-serif";color:black'> on Saturday, October 19, 2019 at 6:30 pm. </span><span style='font-family:"Arial","sans-serif";color:#333333'><a href="http://r20.rs6.net/tn.jsp?f=001FNOFw02__L_UrU61Akw_J25j2tyZwWw7EaQe18GFz6UUJRnrfNHW4JFkOwVjAFiUWNzrqovwk8WJ0qADs-mIG5wxQ87b_MJMXGB-n2RUIMBfCB3S9qes7UPzyCut7bZ3WnGHkIx2RvOX_38_jqs1WLGly-v_6vqUJxXM39FiPs4uh5DrydMvEA==&c=9Svlxdca_7izPUd2isOX2mUzolFU0Tlc8o7Ur_N35HRkSQnpPsxjWQ==&ch=Uqr8NkUnrTsrRRvTm-56RILbRua8HOO5fdQBASG-yys-olxp5ZgPrw==" target="_blank"><b><i><span style='color:#006DB0'>CLICK HERE</span></i></b></a></span><span style='font-family:"Arial","sans-serif";color:black'> for more information.</span><span style='font-family:"Arial","sans-serif";color:#333333'> <o:p></o:p></span></p></div><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:#333333'><o:p> </o:p></span></p></div><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:black'>Registration is now open for </span><b><i><span style='font-family:"Arial","sans-serif";color:#006DB0'>Prostate Cancer International's 4th FREE conference</span></i></b><span style='font-family:"Arial","sans-serif";color:black'> for patients and caregivers on Saturday, November 2nd in Virginia Beach, VA. </span><span style='font-family:"Arial","sans-serif";color:#333333'><a href="http://r20.rs6.net/tn.jsp?f=001FNOFw02__L_UrU61Akw_J25j2tyZwWw7EaQe18GFz6UUJRnrfNHW4JFkOwVjAFiU72JoxGu3GAI_RjU009h09BVqdHsQcL1oANDneaS1OowyZ-dllY2NYA89hlJuu72T96x5dmqBgkxUEHu3qJg1X58fvj_zbgFyE31VrmGhr4OO4oC05s6dgV2mdRluOLwUS31P3J1eO2L6U-BRxIdbEdPlacl0f-Lm39-cG_uIMcWqxwdaPTGnBVqN97PbHGzKNdI1fLT7pj0=&c=9Svlxdca_7izPUd2isOX2mUzolFU0Tlc8o7Ur_N35HRkSQnpPsxjWQ==&ch=Uqr8NkUnrTsrRRvTm-56RILbRua8HOO5fdQBASG-yys-olxp5ZgPrw==" target="_blank"><b><i><span style='color:#006DB0'>CLICK HERE</span></i></b></a></span><span style='font-family:"Arial","sans-serif";color:black'> for more information.</span><span style='font-family:"Arial","sans-serif";color:#333333'> <o:p></o:p></span></p></div><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:black'> </span><span style='font-family:"Arial","sans-serif";color:#333333'><o:p></o:p></span></p></div><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:#333333'>Consider adding to your prostate cancer knowledge with a </span><b><span style='font-family:"Arial","sans-serif";color:#006DB0'>new book by leading expert Dr. Jeffrey Albaugh</span></b><span style='font-family:"Arial","sans-serif";color:#333333'>, who is also a regular contributor to the <i>Hot SHEET</i> <i>Between the Sheets</i> column. Featuring patient stories about hope and guidance for those facing prostate cancer, </span><b><span style='font-family:"Arial","sans-serif";color:#0070C0'>Reclaiming Sex & Intimacy After Prostate Cancer, A Guide for Men and Their Partners, 2nd Edition</span></b><span style='font-family:"Arial","sans-serif";color:#333333'> helps men cope with the challenges of a prostate cancer diagnosis. <a href="http://r20.rs6.net/tn.jsp?f=001FNOFw02__L_UrU61Akw_J25j2tyZwWw7EaQe18GFz6UUJRnrfNHW4EXYrzjvy5c_Tn4QEfQKhdVu-IhLi0lzmKJPVuqNLXZ_PfNmOoK-g67QuaHrYEkWCc7xDKcJAyfeWjnF3TTUd4DNfblUMKGZcH_8ct-PLjz_KbGOpM3VQOdnEFHZXgHQTFMVMPPlfJWt&c=9Svlxdca_7izPUd2isOX2mUzolFU0Tlc8o7Ur_N35HRkSQnpPsxjWQ==&ch=Uqr8NkUnrTsrRRvTm-56RILbRua8HOO5fdQBASG-yys-olxp5ZgPrw==" target="_blank"><b><i><span style='color:#0070C0'>CLICK HERE</span></i></b></a> for more information</span><span style='font-family:"Arial","sans-serif";color:black'>.</span><span style='font-family:"Arial","sans-serif";color:#333333'> <o:p></o:p></span></p></div><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:#333333'><o:p> </o:p></span></p></div><div><p class=MsoNormal><b><span style='font-family:"Arial","sans-serif";color:#333333'>NEWS YOU CAN USE ARTICLES:</span></b><span style='font-family:"Arial","sans-serif";color:#333333'><o:p></o:p></span></p></div><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:#333333'><o:p> </o:p></span></p></div><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:#333333'>Please note that the content below lists only the title of the article rather than a direct link to the content. For access to the full article <a href="http://r20.rs6.net/tn.jsp?f=001FNOFw02__L_UrU61Akw_J25j2tyZwWw7EaQe18GFz6UUJRnrfNHW4FA5Z824Hg_lZ700t7_a_T84Fwf4Zs8zW9KJgNEg3eXiO92tM338dChnTTIFACJdmIO-Zs5hXbn7B3lPaxMJVizLxFrzhCBrfvnibJ3jbUXxt7clRKWXiq0=&c=9Svlxdca_7izPUd2isOX2mUzolFU0Tlc8o7Ur_N35HRkSQnpPsxjWQ==&ch=Uqr8NkUnrTsrRRvTm-56RILbRua8HOO5fdQBASG-yys-olxp5ZgPrw==" target="_blank"><b><i><span style='color:#0078C1'>CLICK HERE</span></i></b></a>.<o:p></o:p></span></p></div><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:#333333'><o:p> </o:p></span></p></div><p class=MsoNormal style='margin-left:30.0pt;text-indent:-12.0pt;mso-list:l5 level1 lfo2'><![if !supportLists]><span style='font-size:10.0pt;font-family:Symbol;color:#333333'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'> </span></span></span><![endif]><span style='font-family:"Arial","sans-serif";color:black'>FDA Grants Priority Review to </span><b><span style='font-family:"Arial","sans-serif";color:#006DB0'>Enzalutamide</span></b><span style='font-family:"Arial","sans-serif";color:black'> for Metastatic Hormone-Sensitive Prostate Cancer</span><span style='font-family:"Arial","sans-serif";color:#333333'> <o:p></o:p></span></p><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:#333333'><o:p> </o:p></span></p></div><p class=MsoNormal style='margin-left:30.0pt;text-indent:-12.0pt;mso-list:l10 level1 lfo3'><![if !supportLists]><span style='font-size:10.0pt;font-family:Symbol;color:#333333'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'> </span></span></span><![endif]><span style='font-family:"Arial","sans-serif";color:black'>Findings from Cedars-Sinai Medical Center Has Provided New Information about </span><b><span style='font-family:"Arial","sans-serif";color:#006DB0'>Prostatectomy</span></b><span style='font-family:"Arial","sans-serif";color:black'> (Association of Social Media Presence with Online Physician Ratings and Surgical Volume Among California Urologists: Observational Study)</span><span style='font-family:"Arial","sans-serif";color:#333333'> <o:p></o:p></span></p><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:#333333'><o:p> </o:p></span></p></div><p class=MsoNormal style='margin-left:30.0pt;text-indent:-12.0pt;mso-list:l3 level1 lfo4'><![if !supportLists]><span style='font-size:10.0pt;font-family:Symbol;color:#333333'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'> </span></span></span><![endif]><span style='font-family:"Arial","sans-serif";color:black'>New Prostate Cancer Study Findings Have Been Reported from Hannover Medical School (Systematic evaluation of written health information on </span><b><span style='font-family:"Arial","sans-serif";color:#006DB0'>PSA based screening in Germany</span></b><span style='font-family:"Arial","sans-serif";color:black'>)</span><span style='font-family:"Arial","sans-serif";color:#333333'> <o:p></o:p></span></p><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:#333333'><o:p> </o:p></span></p></div><p class=MsoNormal style='margin-left:30.0pt;text-indent:-12.0pt;mso-list:l9 level1 lfo5'><![if !supportLists]><span style='font-size:10.0pt;font-family:Symbol;color:#333333'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'> </span></span></span><![endif]><span style='font-family:"Arial","sans-serif";color:black'>Risks of novel </span><b><span style='font-family:"Arial","sans-serif";color:#006DB0'>oral prostate cancer therapies</span></b><span style='font-family:"Arial","sans-serif";color:black'> and pre-existing conditions</span><span style='font-family:"Arial","sans-serif";color:#333333'> <o:p></o:p></span></p><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:#333333'><o:p> </o:p></span></p></div><p class=MsoNormal style='margin-left:30.0pt;text-indent:-12.0pt;mso-list:l13 level1 lfo6'><![if !supportLists]><span style='font-size:10.0pt;font-family:Symbol;color:#333333'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'> </span></span></span><![endif]><span style='font-family:"Arial","sans-serif";color:black'>Researchers identify a possible therapeutic target for </span><b><span style='font-family:"Arial","sans-serif";color:#006DB0'>Kennedy’s disease and prostate cancer</span></b><span style='font-family:"Arial","sans-serif";color:#333333'> <o:p></o:p></span></p><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:#333333'><o:p> </o:p></span></p></div><p class=MsoNormal style='margin-left:30.0pt;text-indent:-12.0pt;mso-list:l4 level1 lfo7'><![if !supportLists]><span style='font-size:10.0pt;font-family:Symbol;color:#333333'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'> </span></span></span><![endif]><span style='font-family:"Arial","sans-serif";color:black'>Study Data from University of Kentucky Update Knowledge of Prostate Cancer (New developments in </span><b><span style='font-family:"Arial","sans-serif";color:#006DB0'>mechanisms of prostate cancer progression</span></b><span style='font-family:"Arial","sans-serif";color:black'>)</span><span style='font-family:"Arial","sans-serif";color:#333333'> <o:p></o:p></span></p><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:#333333'><o:p> </o:p></span></p></div><p class=MsoNormal style='margin-left:30.0pt;text-indent:-12.0pt;mso-list:l2 level1 lfo8'><![if !supportLists]><span style='font-size:10.0pt;font-family:Symbol;color:#333333'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'> </span></span></span><![endif]><span style='font-family:"Arial","sans-serif";color:black'>New Prostate Cancer Findings from Osaka University Graduate School of Medicine Reported (Main Inflammatory Cells and Potentials of </span><b><span style='font-family:"Arial","sans-serif";color:#006DB0'>Anti-Inflammatory Agents in Prostate Cancer)</span></b><span style='font-family:"Arial","sans-serif";color:#333333'> <o:p></o:p></span></p><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:#333333'><o:p> </o:p></span></p></div><p class=MsoNormal style='margin-left:30.0pt;text-indent:-12.0pt;mso-list:l7 level1 lfo9'><![if !supportLists]><span style='font-size:10.0pt;font-family:Symbol;color:#333333'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'> </span></span></span><![endif]><b><span style='font-family:"Arial","sans-serif";color:#006DB0'>Blocking kinase</span></b><span style='font-family:"Arial","sans-serif";color:black'> could provide treatment for prostate cancer</span><span style='font-family:"Arial","sans-serif";color:#333333'> <o:p></o:p></span></p><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:black'></span><span style='font-family:"Arial","sans-serif";color:#333333'><o:p></o:p></span></p></div><p class=MsoNormal style='margin-left:30.0pt;text-indent:-12.0pt;mso-list:l8 level1 lfo10'><![if !supportLists]><span style='font-size:10.0pt;font-family:Symbol;color:#333333'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'> </span></span></span><![endif]><span style='font-family:"Arial","sans-serif";color:black'>Study Data from Polytechnic University of the Marche Region Update Knowledge of Prostate Cancer (Key Role of </span><b><span style='font-family:"Arial","sans-serif";color:#006DB0'>Obesity in Genitourinary Tumors</span></b><span style='font-family:"Arial","sans-serif";color:black'> with Emphasis on Urothelial and Prostate Cancers)</span><span style='font-family:"Arial","sans-serif";color:#333333'> <o:p></o:p></span></p><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:#333333'><o:p> </o:p></span></p></div><p class=MsoNormal style='margin-left:30.0pt;text-indent:-12.0pt;mso-list:l6 level1 lfo11'><![if !supportLists]><span style='font-size:10.0pt;font-family:Symbol;color:#333333'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'> </span></span></span><![endif]><span style='font-family:"Arial","sans-serif";color:black'>Findings from University of Washington Provides New Data on Prostate Cancer (The development and comparative effectiveness of a </span><b><span style='font-family:"Arial","sans-serif";color:#006DB0'>patient-centered prostate biopsy report</span></b><span style='font-family:"Arial","sans-serif";color:black'>: a prospective, randomized study)</span><span style='font-family:"Arial","sans-serif";color:#333333'> <o:p></o:p></span></p><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:#333333'><o:p> </o:p></span></p></div><p class=MsoNormal style='margin-left:30.0pt;text-indent:-12.0pt;mso-list:l11 level1 lfo12'><![if !supportLists]><span style='font-size:10.0pt;font-family:Symbol;color:#333333'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'> </span></span></span><![endif]><span style='font-family:"Arial","sans-serif";color:black'>Data from University of North Carolina Advance Knowledge in Prostate Cancer (</span><b><span style='font-family:"Arial","sans-serif";color:#006DB0'>Proton Therapy for Prostate Cancer</span></b><span style='font-family:"Arial","sans-serif";color:black'>: a Review of the Rationale, Evidence, and Current State)</span><span style='font-family:"Arial","sans-serif";color:#333333'> <o:p></o:p></span></p><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:#333333'><o:p> </o:p></span></p></div><p class=MsoNormal style='margin-left:30.0pt;text-indent:-12.0pt;mso-list:l12 level1 lfo13'><![if !supportLists]><span style='font-size:10.0pt;font-family:Symbol;color:#333333'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'> </span></span></span><![endif]><span style='font-family:"Arial","sans-serif";color:black'>Research from University of Utah Reveals </span><b><span style='font-family:"Arial","sans-serif";color:#006DB0'>New Findings</span></b><span style='font-family:"Arial","sans-serif";color:black'> on Prostate Cancer</span><span style='font-family:"Arial","sans-serif";color:#333333'> <o:p></o:p></span></p><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:#333333'><o:p> </o:p></span></p></div><p class=MsoNormal style='margin-left:30.0pt;text-indent:-12.0pt;mso-list:l0 level1 lfo14'><![if !supportLists]><span style='font-size:10.0pt;font-family:Symbol;color:#333333'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'> </span></span></span><![endif]><b><span style='font-family:"Arial","sans-serif";color:#006DB0'>Presidential Message</span></b><span style='font-family:"Arial","sans-serif";color:black'> on National Prostate Cancer Awareness Month</span><span style='font-family:"Arial","sans-serif";color:#333333'> <o:p></o:p></span></p><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:#333333'><o:p> </o:p></span></p></div><div><p class=MsoNormal><b><span style='font-family:"Arial","sans-serif";color:black'>MORE NEWS:</span></b><span style='font-family:"Arial","sans-serif";color:#333333'><o:p></o:p></span></p></div><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:#333333'><o:p> </o:p></span></p></div><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:#333333'>The journal </span><b><i><span style='font-family:"Arial","sans-serif";color:#006DB0'>Cancer</span></i></b><b><span style='font-family:"Arial","sans-serif";color:#006DB0'> – a journal of the American Cancer Society – published results of the PROCEED registry</span></b><span style='font-family:"Arial","sans-serif";color:#333333'>, which found that men with advanced prostate cancer with low PSA had a<b> </b>median survival of nearly 4 years after treatment with PROVENGE® (sipuleucel-T). PROCEED is the largest real-world study of immunotherapy. Read the <a href="http://r20.rs6.net/tn.jsp?f=001FNOFw02__L_UrU61Akw_J25j2tyZwWw7EaQe18GFz6UUJRnrfNHW4JFkOwVjAFiUsXOu9SOeLB7Ggouko9_MEpIAZ9iMZowq2E--n2yiIFuH3SvX0zFT2LiitOSsmucBPbngLqrDHw2jyrs2eFkc8oTN_w0GP7xQKLcqPVTwGVdxHhWVzlBGWAXdXlbkxcDLKV6eKbmVxRc=&c=9Svlxdca_7izPUd2isOX2mUzolFU0Tlc8o7Ur_N35HRkSQnpPsxjWQ==&ch=Uqr8NkUnrTsrRRvTm-56RILbRua8HOO5fdQBASG-yys-olxp5ZgPrw==" target="_blank"><b><i><span style='color:#0078C1'>Journal article</span></i></b></a> and the <a href="http://r20.rs6.net/tn.jsp?f=001FNOFw02__L_UrU61Akw_J25j2tyZwWw7EaQe18GFz6UUJRnrfNHW4JFkOwVjAFiUbRP7NBpFiElXQNqR-BIP0jJ8OYITTs_xxZSAUvsN6XpVR88zFyxHoZ39VRxqo3Lryi8_1x_AwADP4Fvy4wVFPwS1aHkz-gHUpxskIjBf3JoBobsZ4KuICW2VYzOFVqXztr_sOWbWsurbjr_aMPTZfgbgWmfUARvxfN6gmQrIuWwLr4cwVZk8nRVfXyUPaZOaiD3F4X-8h8VP1Vp4dtmYkw==&c=9Svlxdca_7izPUd2isOX2mUzolFU0Tlc8o7Ur_N35HRkSQnpPsxjWQ==&ch=Uqr8NkUnrTsrRRvTm-56RILbRua8HOO5fdQBASG-yys-olxp5ZgPrw==" target="_blank"><b><i><span style='color:#0078C1'>press release</span></i></b></a>.<o:p></o:p></span></p></div><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:#333333'><o:p> </o:p></span></p></div><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:#333333'>Data Analysis Showed Additional </span><b><span style='font-family:"Arial","sans-serif";color:#006DB0'>Overall Survival Benefit with Sipuleucel-T</span></b><span style='font-family:"Arial","sans-serif";color:#333333'> in African American Patients. <a href="http://r20.rs6.net/tn.jsp?f=001FNOFw02__L_UrU61Akw_J25j2tyZwWw7EaQe18GFz6UUJRnrfNHW4JFkOwVjAFiUTWPra-lJZBZwMvHMEX6h7qCDAJgAwHTWU-w3xCoi3Ag7jea73rx7UE1iNW19pSW15coZiVHaZBeI5V4tjq-KjJjeQvHk_CasHxQHHw1Jh5wIX4JGXmIEh_NQ6BfuIRmKNbg8Dtfv9MFC60muQjfBkaVGB4n9-Kk9_YmWyn5dF5L3A2n5YFF3B90WgyRXrIt7tybN0ZNj88c=&c=9Svlxdca_7izPUd2isOX2mUzolFU0Tlc8o7Ur_N35HRkSQnpPsxjWQ==&ch=Uqr8NkUnrTsrRRvTm-56RILbRua8HOO5fdQBASG-yys-olxp5ZgPrw==" target="_blank"><b><i><span style='color:#0078C1'>CLICK HERE</span></i></b></a> for video.<o:p></o:p></span></p></div><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:#333333'><o:p> </o:p></span></p></div><div><p class=MsoNormal><b><span style='font-family:"Arial","sans-serif";color:#006DB0'>The Prostate Cancer Misdiagnosis Elimination Act</span></b><span style='font-family:"Arial","sans-serif";color:#333333'> has been reported out of both the House Ways and Means Committee (as part of the HEARTS Act, <a href="http://r20.rs6.net/tn.jsp?f=001FNOFw02__L_UrU61Akw_J25j2tyZwWw7EaQe18GFz6UUJRnrfNHW4JFkOwVjAFiUCAFr6u8oXcUKN5CP9h0QpXYDSQiilFtJKTXHl0nY7EDQTaPjzpikMSjqGKqIeLUdtC7A4gAq3mcRakxE2YdOOJ3lO1yCUs-DtdQ9js_A4HDCdAO1hoDUlLl6BrJix_YvChSoK8UZ3RJhazQeLAFfHQ==&c=9Svlxdca_7izPUd2isOX2mUzolFU0Tlc8o7Ur_N35HRkSQnpPsxjWQ==&ch=Uqr8NkUnrTsrRRvTm-56RILbRua8HOO5fdQBASG-yys-olxp5ZgPrw==" target="_blank"><b><i><span style='color:#0078C1'>H.R. 3429</span></i></b></a>) and Energy and Commerce Committee (as part of the REACH Act, <a href="http://r20.rs6.net/tn.jsp?f=001FNOFw02__L_UrU61Akw_J25j2tyZwWw7EaQe18GFz6UUJRnrfNHW4JFkOwVjAFiU6uUKB7pXQLHRzg-rnvZgSMUFZKVjicebjUmOfsxQz9oUWm8cHOvkeCAwCUZR6jOIB65pcFimCF0e3ENjrqoy0sNP4TEfEymo0r0Oq3eqE4HF6I_LvmMg_IFMORNDL2yhcpLeQrUAzXQ=&c=9Svlxdca_7izPUd2isOX2mUzolFU0Tlc8o7Ur_N35HRkSQnpPsxjWQ==&ch=Uqr8NkUnrTsrRRvTm-56RILbRua8HOO5fdQBASG-yys-olxp5ZgPrw==" target="_blank"><b><i><span style='color:#0078C1'>H.R. 2328</span></i></b></a>) this past summer. The Prostate Cancer Misdiagnosis Elimination Act<b> </b>amends the statute to provide Medicare coverage for DSPA testing of all (putative) positive prostate cancer biopsies. </span><b><span style='font-family:"Arial","sans-serif";color:#006DB0'>The bill ensures that the right man gets the right treatment, or no treatment at all by identifying false positive and false negative biopsies. </span></b><span style='font-family:"Arial","sans-serif";color:#333333'>The <a href="http://r20.rs6.net/tn.jsp?f=001FNOFw02__L_UrU61Akw_J25j2tyZwWw7EaQe18GFz6UUJRnrfNHW4JFkOwVjAFiUKPO7_AFSPZJx_t_0oofJegJ5Ykujbj0MskWkNWdqYTEADbTMn9uyvo9tH8jaZEZ2LSaiND8Ujk66dLH2wQERYEBRzq3kkD8FnkggffvKeubK2HClb28QxIAfFLRZC99Z&c=9Svlxdca_7izPUd2isOX2mUzolFU0Tlc8o7Ur_N35HRkSQnpPsxjWQ==&ch=Uqr8NkUnrTsrRRvTm-56RILbRua8HOO5fdQBASG-yys-olxp5ZgPrw==" target="_blank"><b><i><span style='color:#0078C1'>Congressional Budget Office (CBO)</span></i></b></a> recently reevaluated the bill saving over 10-fold from about $7 million to $74 million over 10 years. Us TOO and several other groups support this bill, and we hope to see floor action soon. <o:p></o:p></span></p></div><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:#333333'><o:p> </o:p></span></p></div><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:#333333'>Watch for the October issue of the </span><b><span style='font-family:"Arial","sans-serif";color:#006DB0'>Us TOO Hot SHEET</span></b><span style='font-family:"Arial","sans-serif";color:#333333'> newsletter, and let us know how we can help provide you with educational resources, support services and personal connections to others in the prostate cancer community.<o:p></o:p></span></p></div><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:#333333'><o:p> </o:p></span></p></div><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:#333333'><o:p> </o:p></span></p></div><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:black'>All the best,</span><span style='font-family:"Arial","sans-serif";color:#333333'><o:p></o:p></span></p></div></div></div></td></tr></table></div></td></tr></table></div><p class=MsoNormal align=center style='text-align:center'><o:p> </o:p></p><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse;min-width: 100%'><tr><td width="100%" valign=top style='width:100.0%;padding:0cm 0cm 0cm 0cm;word-wrap: break-word'><div><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse;word-wrap: break-word'><tr><td valign=top style='padding:7.5pt 15.0pt 7.5pt 15.0pt'><div><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 align=left style='border-collapse:collapse;margin-right:3.5pt'><tr style='height:.75pt'><td valign=top style='padding:0cm 0cm 0cm 0cm;height:.75pt'><div><p class=MsoNormal align=center style='text-align:center'><img border=0 width=241 id="_x0000_i1027" src="http://files.constantcontact.com/5f7db5e8601/285ae02b-4062-49c5-94b6-deb06cb11629.jpg"><o:p></o:p></p></div></td><td width=15 valign=top style='width:11.25pt;padding:0cm 0cm 0cm 0cm;height:.75pt'><p class=MsoNormal align=center style='text-align:center;mso-line-height-alt:.75pt'><img border=0 width=15 height=1 id="_x0000_i1028" src="https://imgssl.constantcontact.com/letters/images/sys/S.gif"><o:p></o:p></p></td></tr><tr style='height:.75pt'><td valign=top style='padding:0cm 0cm 0cm 0cm;height:.75pt'><p class=MsoNormal align=center style='text-align:center;mso-line-height-alt:3.75pt'><img border=0 width=1 height=5 id="_x0000_i1029" src="https://imgssl.constantcontact.com/letters/images/sys/S.gif"><o:p></o:p></p></td><td width=5 valign=top style='width:3.75pt;padding:0cm 0cm 0cm 0cm;height:.75pt'><p class=MsoNormal align=center style='text-align:center;mso-line-height-alt:.75pt'><img border=0 width=5 height=1 id="_x0000_i1030" src="https://imgssl.constantcontact.com/letters/images/sys/S.gif"><o:p></o:p></p></td></tr></table></div><div><div><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:#333333'><o:p> </o:p></span></p></div><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:#333333'><o:p> </o:p></span></p></div><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:#333333'><o:p> </o:p></span></p></div><div><p class=MsoNormal><span style='font-size:6.0pt;font-family:"Arial","sans-serif";color:#161D26'></span><span style='font-size:9.0pt;font-family:"Arial","sans-serif";color:#161D26'></span><span style='font-family:"Arial","sans-serif";color:#333333'> <o:p></o:p></span></p></div><div><p class=MsoNormal><span style='font-size:9.0pt;font-family:"Arial","sans-serif";color:#161D26'>Chuck Strand, Chief Executive Officer</span><span style='font-family:"Arial","sans-serif";color:#333333'><o:p></o:p></span></p></div><div><p class=MsoNormal><span style='font-size:9.0pt;font-family:"Arial","sans-serif";color:#161D26'>James Hutson, Development Director</span><span style='font-family:"Arial","sans-serif";color:#333333'><o:p></o:p></span></p></div><div><p class=MsoNormal><span style='font-size:9.0pt;font-family:"Arial","sans-serif";color:#161D26'>Jackie Konieczka, Office Manager</span><span style='font-family:"Arial","sans-serif";color:#333333'><o:p></o:p></span></p></div><div><p class=MsoNormal><span style='font-size:9.0pt;font-family:"Arial","sans-serif";color:#161D26'>Terri Likowski, Program Director - Support Group Services</span><span style='font-family:"Arial","sans-serif";color:#333333'><o:p></o:p></span></p></div><div><p class=MsoNormal><span style='font-size:9.0pt;font-family:"Arial","sans-serif";color:#161D26'>Tim Mix, Communications Director</span><span style='font-family:"Arial","sans-serif";color:#333333'><o:p></o:p></span></p></div></div></div></td></tr></table></div></td></tr></table></div><p class=MsoNormal align=center style='text-align:center'><o:p> </o:p></p><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse;min-width: 100%'><tr><td width="100%" valign=top style='width:100.0%;padding:0cm 0cm 0cm 0cm'><div><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse;min-width: 100%'><tr><td valign=top style='padding:0cm 0cm 0cm 0cm'><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse;min-width: 100%;cursor:default'><tr><td width="100%" valign=top style='width:100.0%;padding:6.75pt 0cm 6.75pt 0cm'><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="93%" style='width:93.0%;border-collapse:collapse;min-width: 93%'><tr style='height:.75pt'><td style='background:black;padding:0cm 0cm 0cm 0cm;height:.75pt'><div><p class=MsoNormal align=center style='text-align:center;mso-line-height-alt:.75pt'><img border=0 width=5 height=1 id="_x0000_i1031" src="https://imgssl.constantcontact.com/letters/images/sys/S.gif"><o:p></o:p></p></div></td></tr></table></div></td></tr></table></div></td></tr></table></div></td></tr></table></div><p class=MsoNormal align=center style='text-align:center'><o:p> </o:p></p><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse;min-width: 100%'><tr><td width="100%" valign=top style='width:100.0%;background:white;padding:0cm 0cm 0cm 0cm;word-wrap: break-word'><div><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse;word-wrap: break-word'><tr><td valign=top style='padding:7.5pt 15.0pt 7.5pt 15.0pt'><div><div><div><p class=MsoNormal align=center style='text-align:center'><span style='font-size:7.5pt;font-family:"Arial","sans-serif";color:#333333'>Connect with Us TOO on Social Media:</span><span style='font-family:"Arial","sans-serif";color:#333333'><o:p></o:p></span></p></div></div></div></td></tr></table></div><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse'><tr><td style='padding:0cm 15.0pt 7.5pt 15.0pt'><div><p class=MsoNormal align=center style='text-align:center'><a href="http://r20.rs6.net/tn.jsp?f=001FNOFw02__L_UrU61Akw_J25j2tyZwWw7EaQe18GFz6UUJRnrfNHW4HRDMha5YTX4U6ReV_JS-jURUGhhHMj0DxrKTq2fxtbu1my0Wyb6Yc0F-HR9RJ3517HMB5RM2Vo8xuw2LevGeBsBUmEVfSaWBeH4w3CRk1CimJet_qH-p5c=&c=9Svlxdca_7izPUd2isOX2mUzolFU0Tlc8o7Ur_N35HRkSQnpPsxjWQ==&ch=Uqr8NkUnrTsrRRvTm-56RILbRua8HOO5fdQBASG-yys-olxp5ZgPrw=="><span style='text-decoration:none'><img border=0 width=32 id="_x0000_i1032" src="https://imgssl.constantcontact.com/galileo/images/templates/Galileo-SocialMedia/facebook-visit-default.png" alt=Facebook> </span></a><a href="http://r20.rs6.net/tn.jsp?f=001FNOFw02__L_UrU61Akw_J25j2tyZwWw7EaQe18GFz6UUJRnrfNHW4HRDMha5YTX4AAktB8Bcbj9AGaPAFOYsdzNOy2cxEG_y6CqOdJQdwlojuAqkGNt0hHfiUtZeT52x8yCp9nhb6XYtfTXxuvqUhA==&c=9Svlxdca_7izPUd2isOX2mUzolFU0Tlc8o7Ur_N35HRkSQnpPsxjWQ==&ch=Uqr8NkUnrTsrRRvTm-56RILbRua8HOO5fdQBASG-yys-olxp5ZgPrw=="><span style='text-decoration:none'><img border=0 width=32 id="_x0000_i1033" src="https://imgssl.constantcontact.com/galileo/images/templates/Galileo-SocialMedia/twitter-visit-default.png" alt=Twitter> </span></a><a href="http://r20.rs6.net/tn.jsp?f=001FNOFw02__L_UrU61Akw_J25j2tyZwWw7EaQe18GFz6UUJRnrfNHW4NOlsuapaISdiWkz6Grzmf50tEMhUac7VaqoDgyuRLitsPmD1zUQK8Xtm1RFHAqH87MhjBRxJRr4vjTJyNdPQz9UEkue9dXOOmHnTRoJz-NtXHgTUR0dajA=&c=9Svlxdca_7izPUd2isOX2mUzolFU0Tlc8o7Ur_N35HRkSQnpPsxjWQ==&ch=Uqr8NkUnrTsrRRvTm-56RILbRua8HOO5fdQBASG-yys-olxp5ZgPrw=="><span style='text-decoration:none'><img border=0 width=32 id="_x0000_i1034" src="https://imgssl.constantcontact.com/galileo/images/templates/Galileo-SocialMedia/linkedin-visit-default.png" alt=LinkedIn> </span></a><o:p></o:p></p></div></td></tr></table></td></tr></table></div></div></td></tr></table></div></td></tr></table></div></td></tr></table></div></td></tr></table></div></div></td></tr><tr><td style='padding:0cm 0cm 0cm 0cm'></td></tr></table><p class=MsoNormal><o:p> </o:p></p><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;background:white;border-collapse:collapse'><tr><td width="100%" valign=top style='width:100.0%;padding:0cm 0cm 0cm 0cm'><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse'><tr><td valign=top style='padding:12.0pt 0cm 12.0pt 0cm'><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=580 style='width:435.0pt;border-collapse:collapse'><tr><td valign=top style='padding:3.0pt 0cm 3.0pt 0cm'><p class=MsoNormal align=center style='text-align:center'><span class=footer-column><span style='font-size:9.0pt;font-family:"Verdana","sans-serif";color:#5D5D5D'>Us TOO International</span></span><span class=footer-mobile-hidden><span style='font-size:9.0pt;font-family:"Verdana","sans-serif";color:#5D5D5D'> | </span></span><span class=footer-column><span style='font-size:9.0pt;font-family:"Verdana","sans-serif";color:#5D5D5D'>2720 S. River Road, Suite 112</span></span><span class=footer-mobile-hidden><span style='font-size:9.0pt;font-family:"Verdana","sans-serif";color:#5D5D5D'>, </span></span><span class=footer-column><span style='font-size:9.0pt;font-family:"Verdana","sans-serif";color:#5D5D5D'>Des Plaines, IL 60018</span></span><span style='font-size:9.0pt;font-family:"Verdana","sans-serif";color:#5D5D5D'> <o:p></o:p></span></p></td></tr><tr><td valign=top style='padding:7.5pt 0cm 7.5pt 0cm'><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 style='border-collapse:collapse'><tr><td valign=top style='padding:3.0pt 0cm 3.0pt 0cm'><p class=MsoNormal align=center style='text-align:center'><span style='font-size:9.0pt;font-family:"Verdana","sans-serif";color:#5D5D5D'><a href="https://visitor.constantcontact.com/do?p=un&m=001KmuJRjw2oGUBkhostjrpJw%3D&ch=1bc4ebc0-6b5e-11e9-96cd-d4ae527b6fcc&ca=fc958698-7619-4387-83c8-dbb90b6d80f7"><span style='color:#5D5D5D'>Unsubscribe glen46nor@gmail.com</span></a> <o:p></o:p></span></p></td></tr><tr><td valign=top style='padding:3.0pt 0cm 3.0pt 0cm'><p class=MsoNormal align=center style='text-align:center'><span style='font-size:9.0pt;font-family:"Verdana","sans-serif";color:#5D5D5D'><a href="https://visitor.constantcontact.com/do?p=oo&m=001KmuJRjw2oGUBkhostjrpJw%3D&ch=1bc4ebc0-6b5e-11e9-96cd-d4ae527b6fcc&ca=fc958698-7619-4387-83c8-dbb90b6d80f7"><span style='color:#5D5D5D'>Update Profile</span></a> | <a href="http://www.constantcontact.com/legal/about-constant-contact"><span style='color:#5D5D5D'>About Constant Contact</span></a> <o:p></o:p></span></p></td></tr><tr><td valign=top style='padding:3.0pt 0cm 3.0pt 0cm'><p class=MsoNormal align=center style='text-align:center'><span style='font-size:9.0pt;font-family:"Verdana","sans-serif";color:#5D5D5D'>Sent by <a href="mailto:chucks@ustoo.org"><span style='color:#5D5D5D;text-decoration:none'>chucks@ustoo.org</span></a> <span class=footer-column>in collaboration with</span> <o:p></o:p></span></p></td></tr></table></div></td></tr><tr><td valign=top style='padding:3.0pt 0cm 3.0pt 0cm'><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=240 style='width:180.0pt;border-collapse:collapse'><tr><td valign=top style='padding:0cm 0cm 2.25pt 7.5pt'><p class=MsoNormal align=center style='text-align:center'><a href="http://www.constantcontact.com/index.jsp?cc=nge&rmc=VF19_3GE"><span style='color:#5D5D5D;text-decoration:none'><img border=0 width=211 id="_x0000_i1035" src="https://imgssl.constantcontact.com/ui/images1/logo_ctct_2x.png" alt="Trusted Email from Constant Contact - Try it FREE today."></span></a><o:p></o:p></p></td></tr><tr><td valign=top style='padding:0cm 0cm 0cm 0cm'><p class=MsoNormal align=center style='text-align:center'><span style='font-size:7.0pt;font-family:"Verdana","sans-serif";color:#5D5D5D'><a href="http://www.constantcontact.com/index.jsp?cc=nge&rmc=VF19_3GE"><span style='color:#5D5D5D;text-decoration:none'>Try email marketing for free today!</span></a> <o:p></o:p></span></p></td></tr></table></div></td></tr></table></div></td></tr></table></div></td></tr></table><p class=MsoNormal><o:p> </o:p></p></div></body></html>